These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 31766991

  • 41. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
    Zhang W, Niu C, He W, Hou T, Sun X, Xu L, Zhang Y.
    Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
    [Abstract] [Full Text] [Related]

  • 42. EphA8 is a prognostic marker for epithelial ovarian cancer.
    Liu X, Xu Y, Jin Q, Wang W, Zhang S, Wang X, Zhang Y, Xu X, Huang J.
    Oncotarget; 2016 Apr 12; 7(15):20801-9. PubMed ID: 26989075
    [Abstract] [Full Text] [Related]

  • 43. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
    Mustea A, Pirvulescu C, Könsgen D, Braicu EI, Yuan S, Sun P, Lichtenegger W, Sehouli J.
    Cytokine; 2008 Apr 12; 42(1):77-84. PubMed ID: 18329282
    [Abstract] [Full Text] [Related]

  • 44. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer.
    Yigit R, Figdor CG, Zusterzeel PL, Pots JM, Torensma R, Massuger LF.
    Eur J Cancer; 2011 Aug 12; 47(12):1883-9. PubMed ID: 21514148
    [Abstract] [Full Text] [Related]

  • 45. Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.
    Tonetti CR, de Souza-Araújo CN, Yoshida A, da Silva RF, Alves PCM, Mazzola TN, Derchain S, Fernandes LGR, Guimarães F.
    Cells; 2021 Jul 06; 10(7):. PubMed ID: 34359872
    [Abstract] [Full Text] [Related]

  • 46. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.
    Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, Li Y.
    Gynecol Oncol; 2007 Jun 06; 105(3):695-702. PubMed ID: 17368732
    [Abstract] [Full Text] [Related]

  • 47. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
    Cai Y, Zhai JJ, Feng BB, Duan XZ, He XJ.
    J Obstet Gynaecol Res; 2014 Jul 06; 40(7):1925-30. PubMed ID: 25056472
    [Abstract] [Full Text] [Related]

  • 48. DEAD-Box Helicase 4 (Ddx4)+ Stem Cells Sustain Tumor Progression in Non-Serous Ovarian Cancers.
    D'Oronzo S, Silvestris E, Lovero D, Cafforio P, Duda L, Cormio G, Paradiso A, Palmirotta R, Silvestris F.
    Int J Mol Sci; 2020 Aug 24; 21(17):. PubMed ID: 32847044
    [Abstract] [Full Text] [Related]

  • 49. Vascular endothelial growth factor in ovarian cyst fluid.
    Boss EA, Massuger LF, Thomas CM, Geurts-Moespot A, Boonstra H, Sweep CG.
    Cancer; 2001 Jan 15; 91(2):371-7. PubMed ID: 11180084
    [Abstract] [Full Text] [Related]

  • 50. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M, Siu A, Clément I, Bidarimath M, Turashvili G, Edwards A, Rahimi K, Mes-Masson AM, Squire JA.
    Br J Cancer; 2015 Mar 31; 112(7):1215-22. PubMed ID: 25826225
    [Abstract] [Full Text] [Related]

  • 51. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].
    Zhao Y, Wang Y, Shen Dh, Song Rn, Xu Q, Li Y, Cui H, Tang J, Wei Lh.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb 18; 43(1):123-8. PubMed ID: 21321635
    [Abstract] [Full Text] [Related]

  • 52. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
    Zhang J, Tang L, Chen Y, Duan Z, Xiao L, Li W, Liu X, Shen L.
    Hum Pathol; 2015 Sep 18; 46(9):1331-40. PubMed ID: 26193797
    [Abstract] [Full Text] [Related]

  • 53. DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.
    Zhang L, Zhang S, Li A, Zhang A, Zhang S, Chen L.
    Int J Mol Med; 2018 Dec 18; 42(6):3065-3072. PubMed ID: 30221689
    [Abstract] [Full Text] [Related]

  • 54. Upregulation of cyclase-associated actin cytoskeleton regulatory protein 2 in epithelial ovarian cancer correlates with aggressive histologic types and worse outcomes.
    Adachi M, Masugi Y, Yamazaki K, Emoto K, Kobayashi Y, Tominaga E, Banno K, Aoki D, Sakamoto M.
    Jpn J Clin Oncol; 2020 Jun 10; 50(6):643-652. PubMed ID: 32211793
    [Abstract] [Full Text] [Related]

  • 55. Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy.
    Tsiatas ML, Gyftaki R, Liacos C, Politi E, Rodolakis A, Dimopoulos MA, Bamias A.
    Int J Gynecol Cancer; 2009 Nov 10; 19(8):1329-34. PubMed ID: 20009885
    [Abstract] [Full Text] [Related]

  • 56. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer.
    Paik ES, Kim JH, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH.
    J Gynecol Oncol; 2018 Jan 10; 29(1):e13. PubMed ID: 29185271
    [Abstract] [Full Text] [Related]

  • 57. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Kim KH, Park SH, Do KH, Kim J, Choi KU, Moon Y.
    Oncotarget; 2016 Nov 01; 7(44):72148-72166. PubMed ID: 27708225
    [Abstract] [Full Text] [Related]

  • 58. SDF-1alpha/CXCL12 and dendritic cells in ovarian cancer microenvironment.
    Wertel I, Polak G, Tarkowski R, Kotarska M.
    Ginekol Pol; 2011 Jun 01; 82(6):421-5. PubMed ID: 21853930
    [Abstract] [Full Text] [Related]

  • 59. RIF1 promotes human epithelial ovarian cancer growth and progression via activating human telomerase reverse transcriptase expression.
    Liu YB, Mei Y, Long J, Zhang Y, Hu DL, Zhou HH.
    J Exp Clin Cancer Res; 2018 Aug 03; 37(1):182. PubMed ID: 30075819
    [Abstract] [Full Text] [Related]

  • 60. Title Prognosis Significance of ZEB2 and TGF-β1 as well as Other Clinical Characteristics in Epithelial Ovarian Cancer.
    Yan Z, Tian X, Wang R, Cheng X, Mi J, Xiong L, Wang Y, Deng J, Jia M.
    Int J Gynecol Cancer; 2017 Sep 03; 27(7):1343-1349. PubMed ID: 30814239
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.